Literature DB >> 11071709

Decreased choline acetyltransferase immunoreactivity in discrete striatal subregions following chronic haloperidol in rats.

J W Grimm1, M A Chapman, D S Zahm, R E See.   

Abstract

Neuronal loss within the basal ganglia has been hypothesized to play a role in movement disorders (e.g., tardive dyskinesia) that often occur following chronic neuroleptic treatment. Previous studies in animal models have provided some support to this possibility, but have not assessed regionally specific changes after chronic neuroleptic administration. The present study examined whether counts of neurons containing acetylcholine, described as large aspiny type II neurons, were altered in subregions of the corpus striatum and nucleus accumbens following chronic haloperidol administration in rats. Rats were administered haloperidol decanoate (21 mg/kg, i.m.) or vehicle every third week for 24 weeks. Following 4 weeks of withdrawal from the drug, predefined regions were examined for choline acetyltransferase (ChAT) immunoreactive (ir) cells. Compared to the vehicle group, the haloperidol group showed significant reductions in ChAT-ir cell counts in the ventrolateral striatum, nucleus accumbens core, and nucleus accumbens lateral shell. No significant differences were found in the other regions examined: dorsolateral striatum, dorsomedial striatum, ventromedial striatum, nucleus accumbens medial shell, and horizontal limb of the diagonal band. These findings indicate that there may be regionally specific alterations in ChAT-ir cells following chronic haloperidol treatment, supporting previous hypotheses of striatal cholinergic cell loss resulting from chronic neuroleptic treatment. More importantly, the regions affected (ventrolateral striatum and nucleus accumbens) are critical in the regulation of oral movements, thus suggesting that alterations in cholinergic cell activity, and perhaps actual loss of cholinergic cells in these regions, may be important in the manifestation of late-onset oral dyskinesia. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11071709     DOI: 10.1002/1098-2396(20010101)39:1<51::AID-SYN7>3.0.CO;2-Z

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  6 in total

1.  Prevention of haloperidol-induced alterations in brain acetylcholinesterase activity by vitamins B co-administration in a rodent model of tardive dyskinesia.

Authors:  Gersilene Valente de Oliveira; Patrícia Xavier Lima Gomes; Fernanda Yvelize Ramos de Araújo; Silvânia Maria Mendes Vasconcelos; Hélio Vitoriano Nobre Júnior; Francisca Cléa Florenço de Sousa; David F de Lucena; Thomas N Hyphantis; André Férrer Carvalho; Danielle Silveira Macêdo
Journal:  Metab Brain Dis       Date:  2012-10-25       Impact factor: 3.584

2.  Decreased number of parvalbumin and cholinergic interneurons in the striatum of individuals with Tourette syndrome.

Authors:  Yuko Kataoka; Paul S A Kalanithi; Heidi Grantz; Michael L Schwartz; Clifford Saper; James F Leckman; Flora M Vaccarino
Journal:  J Comp Neurol       Date:  2010-02-01       Impact factor: 3.215

3.  Cholinergic receptor alterations in the brain stem of spinal cord injured rats.

Authors:  Chinthu Romeo; Anju Thoppil Raveendran; Nandhu Mohan Sobha; Cheramadathukuzhiyil Scaria Paulose
Journal:  Neurochem Res       Date:  2012-11-27       Impact factor: 3.996

Review 4.  Therapeutic Perspective on Tardive Syndrome with Special Reference to Deep Brain Stimulation.

Authors:  Ryoma Morigaki; Hideo Mure; Ryuji Kaji; Shinji Nagahiro; Satoshi Goto
Journal:  Front Psychiatry       Date:  2016-12-26       Impact factor: 4.157

Review 5.  Cholinergic medication for antipsychotic-induced tardive dyskinesia.

Authors:  Irina Tammenmaa-Aho; Rosie Asher; Karla Soares-Weiser; Hanna Bergman
Journal:  Cochrane Database Syst Rev       Date:  2018-03-19

Review 6.  New and emerging treatments for symptomatic tardive dyskinesia.

Authors:  Abdul Qayyum Rana; Zishan M Chaudry; Pierre J Blanchet
Journal:  Drug Des Devel Ther       Date:  2013-11-06       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.